[{"recommendationid":7715409,"lookupkey":{"TPMT": "Poor Metabolizer", "NUDT15": "Indeterminate"},"drugname":"azathioprine","guidelinename":"TPMT, NUDT15 and Thiopurines","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/","implications":{"TPMT": "TPMT PMs have extremely high erythrocyte concentrations of TGN metabolites and no MeMPN compared to TPMT NMs.", "NUDT15": "Greatly increased risk of thiopurine-related leukopenia, neutropenia and myelosuppression. Fatal toxicity possible without dose decrease."},"drugrecommendation":"Consider alternative nonthiopurine immunosuppressant therapy.","classification":"Strong","phenotypes":{"TPMT": "Poor Metabolizer", "NUDT15": "Indeterminate"},"activityscore":{},"population":"general","comments":"Standard starting doses may vary by patient characteristics and/or treatment regimens and according to local clinical practice."}, 
 {"recommendationid":7715406,"lookupkey":{"TPMT": "Possible Intermediate Metabolizer", "NUDT15": "Poor Metabolizer"},"drugname":"azathioprine","guidelinename":"TPMT, NUDT15 and Thiopurines","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/","implications":{"TPMT": "n/a", "NUDT15": "Greatly increased risk of thiopurine-related leukopenia, neutropenia and myelosuppression. Fatal toxicity possible without dose decrease."},"drugrecommendation":"Consider alternative nonthiopurine immunosuppressant therapy.","classification":"Strong","phenotypes":{"TPMT": "Possible Intermediate Metabolizer", "NUDT15": "Poor Metabolizer"},"activityscore":{},"population":"general","comments":"Standard starting doses may vary by patient characteristics and/or treatment regimens and according to local clinical practice."}, 
 {"recommendationid":7715407,"lookupkey":{"TPMT": "Intermediate Metabolizer", "NUDT15": "Poor Metabolizer"},"drugname":"azathioprine","guidelinename":"TPMT, NUDT15 and Thiopurines","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/","implications":{"TPMT": "n/a", "NUDT15": "Greatly increased risk of thiopurine-related leukopenia, neutropenia and myelosuppression. Fatal toxicity possible without dose decrease."},"drugrecommendation":"Consider alternative nonthiopurine immunosuppressant therapy.","classification":"Strong","phenotypes":{"TPMT": "Intermediate Metabolizer", "NUDT15": "Poor Metabolizer"},"activityscore":{},"population":"general","comments":"Standard starting doses may vary by patient characteristics and/or treatment regimens and according to local clinical practice."}, 
 {"recommendationid":7715408,"lookupkey":{"TPMT": "Normal Metabolizer", "NUDT15": "Poor Metabolizer"},"drugname":"azathioprine","guidelinename":"TPMT, NUDT15 and Thiopurines","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/","implications":{"TPMT": "n/a", "NUDT15": "Greatly increased risk of thiopurine-related leukopenia, neutropenia and myelosuppression. Fatal toxicity possible without dose decrease."},"drugrecommendation":"Consider alternative nonthiopurine immunosuppressant therapy.","classification":"Strong","phenotypes":{"TPMT": "Normal Metabolizer", "NUDT15": "Poor Metabolizer"},"activityscore":{},"population":"general","comments":"Standard starting doses may vary by patient characteristics and/or treatment regimens and according to local clinical practice."}, 
 {"recommendationid":7715400,"lookupkey":{"TPMT": "Normal Metabolizer", "NUDT15": "Normal Metabolizer"},"drugname":"azathioprine","guidelinename":"TPMT, NUDT15 and Thiopurines","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/","implications":{"TPMT": "TPMT NMs have lower erythrocyte concentrations of TGN metabolites and higher concentrations of MeMPNs compared to TPMT IMs and TPMT PMs. This is the 'normal' pattern.", "NUDT15": "Normal risk of thiopurine-related leukopenia, neutropenia and myelosuppression."},"drugrecommendation":"Initiate therapy with standard starting dose (e.g., 2 mg/kg/day for autoimmune diseases). During therapy, adjust doses of azathioprine based on disease-specific guidelines. It usually takes at least 2 weeks to reach steady state after each dose adjustment.","classification":"Strong","phenotypes":{"TPMT": "Normal Metabolizer", "NUDT15": "Normal Metabolizer"},"activityscore":{},"population":"general","comments":"Standard starting doses may vary by patient characteristics and/or treatment regimens and according to local clinical practice."}, 
 {"recommendationid":7715401,"lookupkey":{"TPMT": "Normal Metabolizer", "NUDT15": "Intermediate Metabolizer"},"drugname":"azathioprine","guidelinename":"TPMT, NUDT15 and Thiopurines","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/","implications":{"TPMT": "TPMT NMs have lower erythrocyte concentrations of TGN metabolites and higher concentrations of MeMPNs compared to TPMT IMs and TPMT PMs. This is the 'normal' pattern. TPMT IMs have moderate to high erythrocyte concentrations of TGN metabolites and low concentrations of MeMPNs compared to TPMT NMs.", "NUDT15": "Increased risk of thiopurine-related leukopenia, neutropenia and myelosuppression."},"drugrecommendation":"Initiate therapy with reduced starting doses (30-80% of standard starting dose) if standard starting dose is ≥2 mg/kg/day. If starting dose is already below standard starting dose, dose reduction might not be necessary. During therapy, adjust the doses of azathioprine based on the degree of myelosuppression and disease-specific guidelines. It usually takes at least 2-4 weeks of stable dosing to reach steady state after each dose adjustment.","classification":"Strong","phenotypes":{"TPMT": "Normal Metabolizer", "NUDT15": "Intermediate Metabolizer"},"activityscore":{},"population":"general","comments":"Standard starting doses may vary by patient characteristics and/or treatment regimens and according to local clinical practice."}, 
 {"recommendationid":7715402,"lookupkey":{"TPMT": "Normal Metabolizer", "NUDT15": "Possible Intermediate Metabolizer"},"drugname":"azathioprine","guidelinename":"TPMT, NUDT15 and Thiopurines","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/","implications":{"TPMT": "TPMT NMs have lower erythrocyte concentrations of TGN metabolites and higher concentrations of MeMPNs compared to TPMT IMs and TPMT PMs. This is the 'normal' pattern. TPMT IMs have moderate to high erythrocyte concentrations of TGN metabolites and low concentrations of MeMPNs compared to TPMT NMs.", "NUDT15": "Increased risk of thiopurine-related leukopenia, neutropenia and myelosuppression."},"drugrecommendation":"Initiate therapy with reduced starting doses (30-80% of standard starting dose) if standard starting dose is ≥2 mg/kg/day. If starting dose is already below standard starting dose, dose reduction might not be necessary. During therapy, adjust the doses of azathioprine based on the degree of myelosuppression and disease-specific guidelines. It usually takes at least 2-4 weeks of stable dosing to reach steady state after each dose adjustment.","classification":"Strong","phenotypes":{"TPMT": "Normal Metabolizer", "NUDT15": "Possible Intermediate Metabolizer"},"activityscore":{},"population":"general","comments":"Standard starting doses may vary by patient characteristics and/or treatment regimens and according to local clinical practice."}, 
 {"recommendationid":7715403,"lookupkey":{"TPMT": "Intermediate Metabolizer", "NUDT15": "Normal Metabolizer"},"drugname":"azathioprine","guidelinename":"TPMT, NUDT15 and Thiopurines","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/","implications":{"TPMT": "TPMT IMs have moderate to high erythrocyte concentrations of TGN metabolites and low concentrations of MeMPNs compared to TPMT NMs.", "NUDT15": "Increased risk of thiopurine-related leukopenia, neutropenia and myelosuppression."},"drugrecommendation":"Initiate therapy with reduced starting doses (30-80% of standard starting dose) if standard starting dose is ≥2 mg/kg/day. If starting dose is already below standard starting dose, dose reduction might not be necessary. During therapy, adjust the doses of azathioprine based on the degree of myelosuppression and disease-specific guidelines. It usually takes at least 2-4 weeks of stable dosing to reach steady state after each dose adjustment.","classification":"Strong","phenotypes":{"TPMT": "Intermediate Metabolizer", "NUDT15": "Normal Metabolizer"},"activityscore":{},"population":"general","comments":"Standard starting doses may vary by patient characteristics and/or treatment regimens and according to local clinical practice."}, 
 {"recommendationid":7715404,"lookupkey":{"TPMT": "Possible Intermediate Metabolizer", "NUDT15": "Normal Metabolizer"},"drugname":"azathioprine","guidelinename":"TPMT, NUDT15 and Thiopurines","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/","implications":{"TPMT": "TPMT IMs have moderate to high erythrocyte concentrations of TGN metabolites and low concentrations of MeMPNs compared to TPMT NMs.", "NUDT15": "Increased risk of thiopurine-related leukopenia, neutropenia and myelosuppression."},"drugrecommendation":"Initiate therapy with reduced starting doses (30-80% of standard starting dose) if standard starting dose is ≥2 mg/kg/day. If starting dose is already below standard starting dose, dose reduction might not be necessary. During therapy, adjust the doses of azathioprine based on the degree of myelosuppression and disease-specific guidelines. It usually takes at least 2-4 weeks of stable dosing to reach steady state after each dose adjustment.","classification":"Strong","phenotypes":{"TPMT": "Possible Intermediate Metabolizer", "NUDT15": "Normal Metabolizer"},"activityscore":{},"population":"general","comments":"Standard starting doses may vary by patient characteristics and/or treatment regimens and according to local clinical practice."}, 
 {"recommendationid":7715405,"lookupkey":{"TPMT": "Indeterminate", "NUDT15": "Poor Metabolizer"},"drugname":"azathioprine","guidelinename":"TPMT, NUDT15 and Thiopurines","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/","implications":{"TPMT": "n/a", "NUDT15": "Greatly increased risk of thiopurine-related leukopenia, neutropenia and myelosuppression. Fatal toxicity possible without dose decrease."},"drugrecommendation":"Consider alternative nonthiopurine immunosuppressant therapy.","classification":"Strong","phenotypes":{"TPMT": "Indeterminate", "NUDT15": "Poor Metabolizer"},"activityscore":{},"population":"general","comments":"Standard starting doses may vary by patient characteristics and/or treatment regimens and according to local clinical practice."}, 
 {"recommendationid":7715410,"lookupkey":{"TPMT": "Poor Metabolizer", "NUDT15": "Possible Intermediate Metabolizer"},"drugname":"azathioprine","guidelinename":"TPMT, NUDT15 and Thiopurines","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/","implications":{"TPMT": "TPMT PMs have extremely high erythrocyte concentrations of TGN metabolites and no MeMPN compared to TPMT NMs.", "NUDT15": "Greatly increased risk of thiopurine-related leukopenia, neutropenia and myelosuppression. Fatal toxicity possible without dose decrease."},"drugrecommendation":"Consider alternative nonthiopurine immunosuppressant therapy.","classification":"Strong","phenotypes":{"TPMT": "Poor Metabolizer", "NUDT15": "Possible Intermediate Metabolizer"},"activityscore":{},"population":"general","comments":"Standard starting doses may vary by patient characteristics and/or treatment regimens and according to local clinical practice."}, 
 {"recommendationid":7715411,"lookupkey":{"TPMT": "Poor Metabolizer", "NUDT15": "Intermediate Metabolizer"},"drugname":"azathioprine","guidelinename":"TPMT, NUDT15 and Thiopurines","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/","implications":{"TPMT": "TPMT PMs have extremely high erythrocyte concentrations of TGN metabolites and no MeMPN compared to TPMT NMs.", "NUDT15": "Greatly increased risk of thiopurine-related leukopenia, neutropenia and myelosuppression. Fatal toxicity possible without dose decrease."},"drugrecommendation":"Consider alternative nonthiopurine immunosuppressant therapy.","classification":"Strong","phenotypes":{"TPMT": "Poor Metabolizer", "NUDT15": "Intermediate Metabolizer"},"activityscore":{},"population":"general","comments":"Standard starting doses may vary by patient characteristics and/or treatment regimens and according to local clinical practice."}, 
 {"recommendationid":7715412,"lookupkey":{"TPMT": "Poor Metabolizer", "NUDT15": "Normal Metabolizer"},"drugname":"azathioprine","guidelinename":"TPMT, NUDT15 and Thiopurines","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/","implications":{"TPMT": "TPMT PMs have extremely high erythrocyte concentrations of TGN metabolites and no MeMPN compared to TPMT NMs.", "NUDT15": "Greatly increased risk of thiopurine-related leukopenia, neutropenia and myelosuppression. Fatal toxicity possible without dose decrease."},"drugrecommendation":"Consider alternative nonthiopurine immunosuppressant therapy.","classification":"Strong","phenotypes":{"TPMT": "Poor Metabolizer", "NUDT15": "Normal Metabolizer"},"activityscore":{},"population":"general","comments":"Standard starting doses may vary by patient characteristics and/or treatment regimens and according to local clinical practice."}, 
 {"recommendationid":7715413,"lookupkey":{"TPMT": "Poor Metabolizer", "NUDT15": "Poor Metabolizer"},"drugname":"azathioprine","guidelinename":"TPMT, NUDT15 and Thiopurines","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/","implications":{"TPMT": "TPMT PMs have extremely high erythrocyte concentrations of TGN metabolites and no MeMPN compared to TPMT NMs.", "NUDT15": "Greatly increased risk of thiopurine-related leukopenia, neutropenia and myelosuppression. Fatal toxicity possible without dose decrease."},"drugrecommendation":"Consider alternative nonthiopurine immunosuppressant therapy.","classification":"Strong","phenotypes":{"TPMT": "Poor Metabolizer", "NUDT15": "Poor Metabolizer"},"activityscore":{},"population":"general","comments":"Standard starting doses may vary by patient characteristics and/or treatment regimens and according to local clinical practice."}, 
 {"recommendationid":7715414,"lookupkey":{"TPMT": "Intermediate Metabolizer", "NUDT15": "Intermediate Metabolizer"},"drugname":"azathioprine","guidelinename":"TPMT, NUDT15 and Thiopurines","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/","implications":{"TPMT": "TPMT IMs have moderate to high erythrocyte concentrations of TGN metabolites and low concentrations of MeMPNs compared to TPMT NMs.", "NUDT15": "Increased risk of thiopurine-related leukopenia, neutropenia and myelosuppression. Higher risk of toxicity compared to single IM."},"drugrecommendation":"Initiate therapy with reduced starting doses (20%-50% of standard starting dose) if standard starting dose is ≥ 2 mg/kg/day. If starting dose is already below standard starting dose, dose reduction might not be necessary. During therapy, adjust the doses of azathioprine based on the degree of myelosuppression and disease-specific guidelines. It usually takes at least 2-4 weeks of stable dosing to reach steady state after each dose adjustment.","classification":"Moderate","phenotypes":{"TPMT": "Intermediate Metabolizer", "NUDT15": "Intermediate Metabolizer"},"activityscore":{},"population":"general","comments":"Standard starting doses may vary by patient characteristics and/or treatment regimens and according to local clinical practice."}, 
 {"recommendationid":7715415,"lookupkey":{"TPMT": "Possible Intermediate Metabolizer", "NUDT15": "Intermediate Metabolizer"},"drugname":"azathioprine","guidelinename":"TPMT, NUDT15 and Thiopurines","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/","implications":{"TPMT": "TPMT IMs have moderate to high erythrocyte concentrations of TGN metabolites and low concentrations of MeMPNs compared to TPMT NMs.", "NUDT15": "Increased risk of thiopurine-related leukopenia, neutropenia and myelosuppression. Higher risk of toxicity compared to single IM."},"drugrecommendation":"Initiate therapy with reduced starting doses (20%-50% of standard starting dose) if standard starting dose is ≥ 2 mg/kg/day. If starting dose is already below standard starting dose, dose reduction might not be necessary. During therapy, adjust the doses of azathioprine based on the degree of myelosuppression and disease-specific guidelines. It usually takes at least 2-4 weeks of stable dosing to reach steady state after each dose adjustment.","classification":"Moderate","phenotypes":{"TPMT": "Possible Intermediate Metabolizer", "NUDT15": "Intermediate Metabolizer"},"activityscore":{},"population":"general","comments":"Standard starting doses may vary by patient characteristics and/or treatment regimens and according to local clinical practice."}, 
 {"recommendationid":7715416,"lookupkey":{"TPMT": "Intermediate Metabolizer", "NUDT15": "Possible Intermediate Metabolizer"},"drugname":"azathioprine","guidelinename":"TPMT, NUDT15 and Thiopurines","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/","implications":{"TPMT": "TPMT IMs have moderate to high erythrocyte concentrations of TGN metabolites and low concentrations of MeMPNs compared to TPMT NMs.", "NUDT15": "Increased risk of thiopurine-related leukopenia, neutropenia and myelosuppression. Higher risk of toxicity compared to single IM."},"drugrecommendation":"Initiate therapy with reduced starting doses (20%-50% of standard starting dose) if standard starting dose is ≥ 2 mg/kg/day. If starting dose is already below standard starting dose, dose reduction might not be necessary. During therapy, adjust the doses of azathioprine based on the degree of myelosuppression and disease-specific guidelines. It usually takes at least 2-4 weeks of stable dosing to reach steady state after each dose adjustment.","classification":"Moderate","phenotypes":{"TPMT": "Intermediate Metabolizer", "NUDT15": "Possible Intermediate Metabolizer"},"activityscore":{},"population":"general","comments":"Standard starting doses may vary by patient characteristics and/or treatment regimens and according to local clinical practice."}, 
 {"recommendationid":7715417,"lookupkey":{"TPMT": "Possible Intermediate Metabolizer", "NUDT15": "Possible Intermediate Metabolizer"},"drugname":"azathioprine","guidelinename":"TPMT, NUDT15 and Thiopurines","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/","implications":{"TPMT": "TPMT IMs have moderate to high erythrocyte concentrations of TGN metabolites and low concentrations of MeMPNs compared to TPMT NMs.", "NUDT15": "Increased risk of thiopurine-related leukopenia, neutropenia and myelosuppression. Higher risk of toxicity compared to single IM."},"drugrecommendation":"Initiate therapy with reduced starting doses (20%-50% of standard starting dose) if standard starting dose is ≥ 2 mg/kg/day. If starting dose is already below standard starting dose, dose reduction might not be necessary. During therapy, adjust the doses of azathioprine based on the degree of myelosuppression and disease-specific guidelines. It usually takes at least 2-4 weeks of stable dosing to reach steady state after each dose adjustment.","classification":"Moderate","phenotypes":{"TPMT": "Possible Intermediate Metabolizer", "NUDT15": "Possible Intermediate Metabolizer"},"activityscore":{},"population":"general","comments":"Standard starting doses may vary by patient characteristics and/or treatment regimens and according to local clinical practice."}, 
 {"recommendationid":7715418,"lookupkey":{"TPMT": "Normal Metabolizer", "NUDT15": "Indeterminate"},"drugname":"azathioprine","guidelinename":"TPMT, NUDT15 and Thiopurines","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/","implications":{"TPMT": "TPMT NMs have lower erythrocyte concentrations of TGN metabolites and higher concentrations of MeMPNs compared to TPMT IMs and TPMT PMs. This is the 'normal' pattern.", "NUDT15": "Normal risk of thiopurine-related leukopenia, neutropenia and myelosuppression."},"drugrecommendation":"Based on TPMT, initiate therapy with standard starting dose (e.g., 2 mg/kg/day for autoimmune diseases). During therapy, adjust doses of azathioprine based on disease-specific guidelines. It usually takes at least 2 weeks to reach steady state after each dose adjustment.","classification":"Strong","phenotypes":{"TPMT": "Normal Metabolizer", "NUDT15": "Indeterminate"},"activityscore":{},"population":"general","comments":"Standard starting doses may vary by patient characteristics and/or treatment regimens and according to local clinical practice."}, 
 {"recommendationid":7715419,"lookupkey":{"TPMT": "Intermediate Metabolizer", "NUDT15": "Indeterminate"},"drugname":"azathioprine","guidelinename":"TPMT, NUDT15 and Thiopurines","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/","implications":{"TPMT": "TPMT IMs have moderate to high erythrocyte concentrations of TGN metabolites and low concentrations of MeMPNs compared to TPMT NMs.", "NUDT15": "Increased risk of thiopurine-related leukopenia, neutropenia and myelosuppression."},"drugrecommendation":"Based on TPMT, initiate therapy with reduced starting doses (30-80% of standard starting dose) if standard starting dose is ≥2 mg/kg/day. If starting dose is already below standard starting dose, dose reduction might not be necessary. During therapy, adjust the doses of azathioprine based on the degree of myelosuppression and disease-specific guidelines. It usually takes at least 2-4 weeks of stable dosing to reach steady state after each dose adjustment.","classification":"Strong","phenotypes":{"TPMT": "Intermediate Metabolizer", "NUDT15": "Indeterminate"},"activityscore":{},"population":"general","comments":"Standard starting doses may vary by patient characteristics and/or treatment regimens and according to local clinical practice."}, 
 {"recommendationid":7715420,"lookupkey":{"TPMT": "Possible Intermediate Metabolizer", "NUDT15": "Indeterminate"},"drugname":"azathioprine","guidelinename":"TPMT, NUDT15 and Thiopurines","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/","implications":{"TPMT": "TPMT IMs have moderate to high erythrocyte concentrations of TGN metabolites and low concentrations of MeMPNs compared to TPMT NMs.", "NUDT15": "Increased risk of thiopurine-related leukopenia, neutropenia and myelosuppression."},"drugrecommendation":"Based on TPMT, initiate therapy with reduced starting doses (30-80% of standard starting dose) if standard starting dose is ≥2 mg/kg/day. If starting dose is already below standard starting dose, dose reduction might not be necessary. During therapy, adjust the doses of azathioprine based on the degree of myelosuppression and disease-specific guidelines. It usually takes at least 2-4 weeks of stable dosing to reach steady state after each dose adjustment.","classification":"Strong","phenotypes":{"TPMT": "Possible Intermediate Metabolizer", "NUDT15": "Indeterminate"},"activityscore":{},"population":"general","comments":"Standard starting doses may vary by patient characteristics and/or treatment regimens and according to local clinical practice."}, 
 {"recommendationid":7715421,"lookupkey":{"TPMT": "Indeterminate", "NUDT15": "Normal Metabolizer"},"drugname":"azathioprine","guidelinename":"TPMT, NUDT15 and Thiopurines","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/","implications":{"TPMT": "n/a", "NUDT15": "Normal risk of thiopurine-related leukopenia, neutropenia and myelosuppression."},"drugrecommendation":"Based on NUDT15, initiate therapy with standard starting dose (e.g., 2 mg/kg/day for autoimmune diseases). During therapy, adjust doses of azathioprine based on disease-specific guidelines. It usually takes at least 2 weeks to reach steady state after each dose adjustment.","classification":"Strong","phenotypes":{"TPMT": "Indeterminate", "NUDT15": "Normal Metabolizer"},"activityscore":{},"population":"general","comments":"Standard starting doses may vary by patient characteristics and/or treatment regimens and according to local clinical practice."}, 
 {"recommendationid":7715422,"lookupkey":{"TPMT": "Indeterminate", "NUDT15": "Intermediate Metabolizer"},"drugname":"azathioprine","guidelinename":"TPMT, NUDT15 and Thiopurines","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/","implications":{"TPMT": "n/a", "NUDT15": "Increased risk of thiopurine-related leukopenia, neutropenia and myelosuppression."},"drugrecommendation":"Based on NUDT15, initiate therapy with reduced starting doses (30-80% of standard starting dose) if standard starting dose is ≥2 mg/kg/day. If starting dose is already below standard starting dose, dose reduction might not be necessary. During therapy, adjust the doses of azathioprine based on the degree of myelosuppression and disease-specific guidelines. It usually takes at least 2-4 weeks of stable dosing to reach steady state after each dose adjustment.","classification":"Strong","phenotypes":{"TPMT": "Indeterminate", "NUDT15": "Intermediate Metabolizer"},"activityscore":{},"population":"general","comments":"Standard starting doses may vary by patient characteristics and/or treatment regimens and according to local clinical practice."}, 
 {"recommendationid":7715423,"lookupkey":{"TPMT": "Indeterminate", "NUDT15": "Possible Intermediate Metabolizer"},"drugname":"azathioprine","guidelinename":"TPMT, NUDT15 and Thiopurines","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/","implications":{"TPMT": "n/a", "NUDT15": "Increased risk of thiopurine-related leukopenia, neutropenia and myelosuppression."},"drugrecommendation":"Based on NUDT15, initiate therapy with reduced starting doses (30-80% of standard starting dose) if standard starting dose is ≥2 mg/kg/day. If starting dose is already below standard starting dose, dose reduction might not be necessary. During therapy, adjust the doses of azathioprine based on the degree of myelosuppression and disease-specific guidelines. It usually takes at least 2-4 weeks of stable dosing to reach steady state after each dose adjustment.","classification":"Strong","phenotypes":{"TPMT": "Indeterminate", "NUDT15": "Possible Intermediate Metabolizer"},"activityscore":{},"population":"general","comments":"Standard starting doses may vary by patient characteristics and/or treatment regimens and according to local clinical practice."}, 
 {"recommendationid":7715424,"lookupkey":{"TPMT": "Indeterminate", "NUDT15": "Indeterminate"},"drugname":"azathioprine","guidelinename":"TPMT, NUDT15 and Thiopurines","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/","implications":{"TPMT": "n/a", "NUDT15": "n/a"},"drugrecommendation":"Neither TPMT or NUDT15 phenotype could be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.","classification":"Strong","phenotypes":{"TPMT": "Indeterminate", "NUDT15": "Indeterminate"},"activityscore":{},"population":"general","comments":null}, 
 {"recommendationid":7715425,"lookupkey":{"TPMT": "No Result", "NUDT15": "Normal Metabolizer"},"drugname":"azathioprine","guidelinename":"TPMT, NUDT15 and Thiopurines","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/","implications":{"TPMT": "n/a", "NUDT15": "Normal risk of thiopurine-related leukopenia, neutropenia and myelosuppression."},"drugrecommendation":"Based on NUDT15, initiate therapy with standard starting dose (e.g., 2 mg/kg/day for autoimmune diseases). During therapy, adjust doses of azathioprine based on disease-specific guidelines. It usually takes at least 2 weeks to reach steady state after each dose adjustment.","classification":"Strong","phenotypes":{"TPMT": "No Result", "NUDT15": "Normal Metabolizer"},"activityscore":{},"population":"general","comments":"Standard starting doses may vary by patient characteristics and/or treatment regimens and according to local clinical practice."}, 
 {"recommendationid":7715426,"lookupkey":{"TPMT": "No Result", "NUDT15": "Intermediate Metabolizer"},"drugname":"azathioprine","guidelinename":"TPMT, NUDT15 and Thiopurines","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/","implications":{"TPMT": "n/a", "NUDT15": "Increased risk of thiopurine-related leukopenia, neutropenia and myelosuppression."},"drugrecommendation":"Based on NUDT15, initiate therapy with reduced starting doses (30-80% of standard starting dose) if standard starting dose is ≥2 mg/kg/day. If starting dose is already below standard starting dose, dose reduction might not be necessary. During therapy, adjust the doses of azathioprine based on the degree of myelosuppression and disease-specific guidelines. It usually takes at least 2-4 weeks of stable dosing to reach steady state after each dose adjustment.","classification":"Strong","phenotypes":{"TPMT": "No Result", "NUDT15": "Intermediate Metabolizer"},"activityscore":{},"population":"general","comments":"Standard starting doses may vary by patient characteristics and/or treatment regimens and according to local clinical practice."}, 
 {"recommendationid":7715427,"lookupkey":{"TPMT": "No Result", "NUDT15": "Possible Intermediate Metabolizer"},"drugname":"azathioprine","guidelinename":"TPMT, NUDT15 and Thiopurines","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/","implications":{"TPMT": "n/a", "NUDT15": "Increased risk of thiopurine-related leukopenia, neutropenia and myelosuppression."},"drugrecommendation":"Based on NUDT15, initiate therapy with reduced starting doses (30-80% of standard starting dose) if standard starting dose is ≥2 mg/kg/day. If starting dose is already below standard starting dose, dose reduction might not be necessary. During therapy, adjust the doses of azathioprine based on the degree of myelosuppression and disease-specific guidelines. It usually takes at least 2-4 weeks of stable dosing to reach steady state after each dose adjustment.","classification":"Strong","phenotypes":{"TPMT": "No Result", "NUDT15": "Possible Intermediate Metabolizer"},"activityscore":{},"population":"general","comments":"Standard starting doses may vary by patient characteristics and/or treatment regimens and according to local clinical practice."}, 
 {"recommendationid":7715428,"lookupkey":{"TPMT": "No Result", "NUDT15": "Poor Metabolizer"},"drugname":"azathioprine","guidelinename":"TPMT, NUDT15 and Thiopurines","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/","implications":{"TPMT": "n/a", "NUDT15": "Greatly increased risk of thiopurine-related leukopenia, neutropenia and myelosuppression. Fatal toxicity possible without dose decrease."},"drugrecommendation":"Consider alternative nonthiopurine immunosuppressant therapy.","classification":"Strong","phenotypes":{"TPMT": "No Result", "NUDT15": "Poor Metabolizer"},"activityscore":{},"population":"general","comments":null}, 
 {"recommendationid":7715429,"lookupkey":{"TPMT": "No Result", "NUDT15": "Indeterminate"},"drugname":"azathioprine","guidelinename":"TPMT, NUDT15 and Thiopurines","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/","implications":{"TPMT": "n/a", "NUDT15": "n/a"},"drugrecommendation":"Neither TPMT or NUDT15 phenotype could be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.","classification":"Strong","phenotypes":{"TPMT": "No Result", "NUDT15": "Indeterminate"},"activityscore":{},"population":"general","comments":null}, 
 {"recommendationid":7715430,"lookupkey":{"TPMT": "Normal Metabolizer", "NUDT15": "No Result"},"drugname":"azathioprine","guidelinename":"TPMT, NUDT15 and Thiopurines","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/","implications":{"TPMT": "TPMT NMs have lower erythrocyte concentrations of TGN metabolites and higher concentrations of MeMPNs compared to TPMT IMs and TPMT PMs. This is the 'normal' pattern.", "NUDT15": "Normal risk of thiopurine-related leukopenia, neutropenia and myelosuppression."},"drugrecommendation":"Based on TPMT, initiate therapy with standard starting dose (e.g., 2 mg/kg/day for autoimmune diseases). During therapy, adjust doses of azathioprine based on disease-specific guidelines. It usually takes at least 2 weeks to reach steady state after each dose adjustment.","classification":"Strong","phenotypes":{"TPMT": "Normal Metabolizer", "NUDT15": "No Result"},"activityscore":{},"population":"general","comments":"Standard starting doses may vary by patient characteristics and/or treatment regimens and according to local clinical practice."}, 
 {"recommendationid":7715431,"lookupkey":{"TPMT": "Intermediate Metabolizer", "NUDT15": "No Result"},"drugname":"azathioprine","guidelinename":"TPMT, NUDT15 and Thiopurines","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/","implications":{"TPMT": "TPMT IMs have moderate to high erythrocyte concentrations of TGN metabolites and low concentrations of MeMPNs compared to TPMT NMs.", "NUDT15": "Increased risk of thiopurine-related leukopenia, neutropenia and myelosuppression."},"drugrecommendation":"Based on TPMT, initiate therapy with reduced starting doses (30-80% of standard starting dose) if standard starting dose is ≥2 mg/kg/day. If starting dose is already below standard starting dose, dose reduction might not be necessary. During therapy, adjust the doses of azathioprine based on the degree of myelosuppression and disease-specific guidelines. It usually takes at least 2-4 weeks of stable dosing to reach steady state after each dose adjustment.","classification":"Strong","phenotypes":{"TPMT": "Intermediate Metabolizer", "NUDT15": "No Result"},"activityscore":{},"population":"general","comments":"Standard starting doses may vary by patient characteristics and/or treatment regimens and according to local clinical practice."}, 
 {"recommendationid":7715432,"lookupkey":{"TPMT": "Possible Intermediate Metabolizer", "NUDT15": "No Result"},"drugname":"azathioprine","guidelinename":"TPMT, NUDT15 and Thiopurines","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/","implications":{"TPMT": "TPMT IMs have moderate to high erythrocyte concentrations of TGN metabolites and low concentrations of MeMPNs compared to TPMT NMs.", "NUDT15": "Increased risk of thiopurine-related leukopenia, neutropenia and myelosuppression."},"drugrecommendation":"Based on TPMT, initiate therapy with reduced starting doses (30-80% of standard starting dose) if standard starting dose is ≥2 mg/kg/day. If starting dose is already below standard starting dose, dose reduction might not be necessary. During therapy, adjust the doses of azathioprine based on the degree of myelosuppression and disease-specific guidelines. It usually takes at least 2-4 weeks of stable dosing to reach steady state after each dose adjustment.","classification":"Strong","phenotypes":{"TPMT": "Possible Intermediate Metabolizer", "NUDT15": "No Result"},"activityscore":{},"population":"general","comments":"Standard starting doses may vary by patient characteristics and/or treatment regimens and according to local clinical practice."}, 
 {"recommendationid":7715433,"lookupkey":{"TPMT": "Poor Metabolizer", "NUDT15": "No Result"},"drugname":"azathioprine","guidelinename":"TPMT, NUDT15 and Thiopurines","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/","implications":{"TPMT": "TPMT PMs have extremely high erythrocyte concentrations of TGN metabolites and no MeMPN compared to TPMT NMs.", "NUDT15": "Greatly increased risk of thiopurine-related leukopenia, neutropenia and myelosuppression. Fatal toxicity possible without dose decrease."},"drugrecommendation":"Consider alternative nonthiopurine immunosuppressant therapy.","classification":"Strong","phenotypes":{"TPMT": "Poor Metabolizer", "NUDT15": "No Result"},"activityscore":{},"population":"general","comments":null}, 
 {"recommendationid":7715434,"lookupkey":{"TPMT": "Indeterminate", "NUDT15": "No Result"},"drugname":"azathioprine","guidelinename":"TPMT, NUDT15 and Thiopurines","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/","implications":{"TPMT": "n/a", "NUDT15": "n/a"},"drugrecommendation":"Neither TPMT or NUDT15 phenotype could be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.","classification":"Strong","phenotypes":{"TPMT": "Indeterminate", "NUDT15": "No Result"},"activityscore":{},"population":"general","comments":null}, 
 {"recommendationid":7715773,"lookupkey":{"CYP2D6": "≥3.75"},"drugname":"codeine","guidelinename":"CYP2D6, OPRM1, COMT, and Opioids","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/","implications":{"CYP2D6": "Increased formation of morphine leading to higher risk of toxicity"},"drugrecommendation":"Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.","classification":"Strong","phenotypes":{"CYP2D6": "Ultrarapid Metabolizer"},"activityscore":{"CYP2D6": "≥3.75"},"population":"general","comments":"n/a"}, 
 {"recommendationid":7715774,"lookupkey":{"CYP2D6": "≥5.0"},"drugname":"codeine","guidelinename":"CYP2D6, OPRM1, COMT, and Opioids","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/","implications":{"CYP2D6": "Increased formation of morphine leading to higher risk of toxicity"},"drugrecommendation":"Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.","classification":"Strong","phenotypes":{"CYP2D6": "Ultrarapid Metabolizer"},"activityscore":{"CYP2D6": "≥5.0"},"population":"general","comments":"n/a"}, 
 {"recommendationid":7715730,"lookupkey":{"CYP2C19": "Ultrarapid Metabolizer"},"drugname":"clopidogrel","guidelinename":"CYP2C19 and Clopidogrel","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-clopidogrel-and-cyp2c19/","implications":{"CYP2C19": "Increased clopidogrel active metabolite formation; lower on-treatment platelet reactivity; no association with higher bleeding risk"},"drugrecommendation":"If considering clopidogrel, use at standard dose (75 mg/day)","classification":"Strong","phenotypes":{"CYP2C19": "Ultrarapid Metabolizer"},"activityscore":{},"population":"CVI ACS PCI ","comments":"For cardiovascular indications of acute coronary syndrome (ACS) and/or percutaneous coronary intervention (PCI). ACS and/or PCI includes patients undergoing PCI for an ACS or non-ACS (elective) indication."}, 
 {"recommendationid":7715731,"lookupkey":{"CYP2C19": "Rapid Metabolizer"},"drugname":"clopidogrel","guidelinename":"CYP2C19 and Clopidogrel","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-clopidogrel-and-cyp2c19/","implications":{"CYP2C19": "Normal or increased clopidogrel active metabolite formation; normal or lower on-treatment platelet reactivity; no association with higher bleeding risk"},"drugrecommendation":"If considering clopidogrel, use at standard dose (75 mg/day)","classification":"Strong","phenotypes":{"CYP2C19": "Rapid Metabolizer"},"activityscore":{},"population":"CVI ACS PCI ","comments":"For cardiovascular indications of acute coronary syndrome (ACS) and/or percutaneous coronary intervention (PCI). ACS and/or PCI includes patients undergoing PCI for an ACS or non-ACS (elective) indication."}, 
 {"recommendationid":7715732,"lookupkey":{"CYP2C19": "Normal Metabolizer"},"drugname":"clopidogrel","guidelinename":"CYP2C19 and Clopidogrel","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-clopidogrel-and-cyp2c19/","implications":{"CYP2C19": "Normal clopidogrel active metabolite formation; normal on-treatment platelet reactivity"},"drugrecommendation":"If considering clopidogrel, use at standard dose (75 mg/day)","classification":"Strong","phenotypes":{"CYP2C19": "Normal Metabolizer"},"activityscore":{},"population":"CVI ACS PCI ","comments":"For cardiovascular indications of acute coronary syndrome (ACS) and/or percutaneous coronary intervention (PCI). ACS and/or PCI includes patients undergoing PCI for an ACS or non-ACS (elective) indication."}, 
 {"recommendationid":7715775,"lookupkey":{"CYP2D6": "≥6.0"},"drugname":"codeine","guidelinename":"CYP2D6, OPRM1, COMT, and Opioids","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/","implications":{"CYP2D6": "Increased formation of morphine leading to higher risk of toxicity"},"drugrecommendation":"Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.","classification":"Strong","phenotypes":{"CYP2D6": "Ultrarapid Metabolizer"},"activityscore":{"CYP2D6": "≥6.0"},"population":"general","comments":"n/a"}, 
 {"recommendationid":7715733,"lookupkey":{"CYP2C19": "Likely Intermediate Metabolizer"},"drugname":"clopidogrel","guidelinename":"CYP2C19 and Clopidogrel","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-clopidogrel-and-cyp2c19/","implications":{"CYP2C19": "Reduced clopidogrel active metabolite formation; increased on-treatment platelet reactivity; increased risk for adverse cardiac and cerebrovascular events"},"drugrecommendation":"Avoid standard dose clopidogrel (75 mg) if possible. Use prasugrel or ticagrelor at standard dose if no contraindication.","classification":"Strong","phenotypes":{"CYP2C19": "Likely Intermediate Metabolizer"},"activityscore":{},"population":"CVI ACS PCI ","comments":"For cardiovascular indications of acute coronary syndrome (ACS) and/or percutaneous coronary intervention (PCI). ACS and/or PCI includes patients undergoing PCI for an ACS or non-ACS (elective) indication. The strength of recommendation for \"likely\" phenotypes are the same as their respective confirmed phenotypes. \"Likely\" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding \"likely\" phenotype."}, 
 {"recommendationid":7715734,"lookupkey":{"CYP2C19": "Intermediate Metabolizer"},"drugname":"clopidogrel","guidelinename":"CYP2C19 and Clopidogrel","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-clopidogrel-and-cyp2c19/","implications":{"CYP2C19": "Reduced clopidogrel active metabolite formation; increased on-treatment platelet reactivity; increased risk for adverse cardiac and cerebrovascular events"},"drugrecommendation":"Avoid standard dose (75 mg) clopidogrel if possible. Use prasugrel or ticagrelor at standard dose if no contraindication.","classification":"Strong","phenotypes":{"CYP2C19": "Intermediate Metabolizer"},"activityscore":{},"population":"CVI ACS PCI ","comments":"For cardiovascular indications of acute coronary syndrome (ACS) and/or percutaneous coronary intervention (PCI). ACS and/or PCI includes patients undergoing PCI for an ACS or non-ACS (elective) indication."}, 
 {"recommendationid":7715735,"lookupkey":{"CYP2C19": "Likely Poor Metabolizer"},"drugname":"clopidogrel","guidelinename":"CYP2C19 and Clopidogrel","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-clopidogrel-and-cyp2c19/","implications":{"CYP2C19": "Significantly reduced clopidogrel active metabolite formation; increased on-treatment platelet reactivity; increased risk for adverse cardiac and cerebrovascular events"},"drugrecommendation":"Avoid clopidogrel if possible. Use prasugrel or ticagrelor at standard dose if no contraindication.","classification":"Strong","phenotypes":{"CYP2C19": "Likely Poor Metabolizer"},"activityscore":{},"population":"CVI ACS PCI ","comments":"For cardiovascular indications of acute coronary syndrome (ACS) and/or percutaneous coronary intervention (PCI). ACS and/or PCI includes patients undergoing PCI for an ACS or non-ACS (elective) indication. The strength of recommendation for \"likely\" phenotypes are the same as their respective confirmed phenotypes. \"Likely\" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding \"likely\" phenotype."}, 
 {"recommendationid":7715736,"lookupkey":{"CYP2C19": "Poor Metabolizer"},"drugname":"clopidogrel","guidelinename":"CYP2C19 and Clopidogrel","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-clopidogrel-and-cyp2c19/","implications":{"CYP2C19": "Significantly reduced clopidogrel active metabolite formation; increased on-treatment platelet reactivity; increased risk for adverse cardiac and cerebrovascular events"},"drugrecommendation":"Avoid clopidogrel if possible. Use prasugrel or ticagrelor at standard dose if no contraindication.","classification":"Strong","phenotypes":{"CYP2C19": "Poor Metabolizer"},"activityscore":{},"population":"CVI ACS PCI ","comments":"For cardiovascular indications of acute coronary syndrome (ACS) and/or percutaneous coronary intervention (PCI). ACS and/or PCI includes patients undergoing PCI for an ACS or non-ACS (elective) indication."}, 
 {"recommendationid":7715737,"lookupkey":{"CYP2C19": "Indeterminate"},"drugname":"clopidogrel","guidelinename":"CYP2C19 and Clopidogrel","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-clopidogrel-and-cyp2c19/","implications":{"CYP2C19": "n/a"},"drugrecommendation":"No recommendation","classification":"No Recommendation","phenotypes":{"CYP2C19": "Indeterminate"},"activityscore":{},"population":"CVI ACS PCI ","comments":"n/a"}, 
 {"recommendationid":7715738,"lookupkey":{"CYP2C19": "Ultrarapid Metabolizer"},"drugname":"clopidogrel","guidelinename":"CYP2C19 and Clopidogrel","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-clopidogrel-and-cyp2c19/","implications":{"CYP2C19": "Increased clopidogrel active metabolite formation; lower on-treatment platelet reactivity; no association with higher bleeding risk"},"drugrecommendation":"No recommendation","classification":"No Recommendation","phenotypes":{"CYP2C19": "Ultrarapid Metabolizer"},"activityscore":{},"population":"CVI non-ACS non-PCI","comments":"For non-acute coronary syndrome (non-ACS) and non-percutaneous coronary intervention (non-PCI) cardiovascular indications. Non-ACS, non-PCI cardiovascular indications include peripheral arterial disease and stable coronary artery disease following a recent myocardial infarction outside the setting of PCI."}, 
 {"recommendationid":7715739,"lookupkey":{"CYP2C19": "Rapid Metabolizer"},"drugname":"clopidogrel","guidelinename":"CYP2C19 and Clopidogrel","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-clopidogrel-and-cyp2c19/","implications":{"CYP2C19": "Normal or increased clopidogrel active metabolite formation; normal or lower on-treatment platelet reactivity; no association with higher bleeding risk"},"drugrecommendation":"No recommendation","classification":"No Recommendation","phenotypes":{"CYP2C19": "Rapid Metabolizer"},"activityscore":{},"population":"CVI non-ACS non-PCI","comments":"For non-acute coronary syndrome (non-ACS) and non-percutaneous coronary intervention (non-PCI) cardiovascular indications. Non-ACS, non-PCI cardiovascular indications include peripheral arterial disease and stable coronary artery disease following a recent myocardial infarction outside the setting of PCI."}, 
 {"recommendationid":7715740,"lookupkey":{"CYP2C19": "Normal Metabolizer"},"drugname":"clopidogrel","guidelinename":"CYP2C19 and Clopidogrel","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-clopidogrel-and-cyp2c19/","implications":{"CYP2C19": "Normal clopidogrel active metabolite formation; normal on-treatment platelet reactivity"},"drugrecommendation":"If considering clopidogrel, use at standard dose (75 mg/day)","classification":"Strong","phenotypes":{"CYP2C19": "Normal Metabolizer"},"activityscore":{},"population":"CVI non-ACS non-PCI","comments":"For non-acute coronary syndrome (non-ACS) and non-percutaneous coronary intervention (non-PCI) cardiovascular indications. Non-ACS, non-PCI cardiovascular indications include peripheral arterial disease and stable coronary artery disease following a recent myocardial infarction outside the setting of PCI."}, 
 {"recommendationid":7715741,"lookupkey":{"CYP2C19": "Likely Intermediate Metabolizer"},"drugname":"clopidogrel","guidelinename":"CYP2C19 and Clopidogrel","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-clopidogrel-and-cyp2c19/","implications":{"CYP2C19": "Reduced clopidogrel active metabolite formation; increased on-treatment platelet reactivity; increased risk for adverse cardiac and cerebrovascular events"},"drugrecommendation":"No recommendation","classification":"No Recommendation","phenotypes":{"CYP2C19": "Likely Intermediate Metabolizer"},"activityscore":{},"population":"CVI non-ACS non-PCI","comments":"For non-acute coronary syndrome (non-ACS) and non-percutaneous coronary intervention (non-PCI) cardiovascular indications. Non-ACS, non-PCI cardiovascular indications include peripheral arterial disease and stable coronary artery disease following a recent myocardial infarction outside the setting of PCI. The strength of recommendation for \"likely\" phenotypes are the same as their respective confirmed phenotypes. \"Likely\" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding \"likely\" phenotype."}, 
 {"recommendationid":7715742,"lookupkey":{"CYP2C19": "Intermediate Metabolizer"},"drugname":"clopidogrel","guidelinename":"CYP2C19 and Clopidogrel","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-clopidogrel-and-cyp2c19/","implications":{"CYP2C19": "Reduced clopidogrel active metabolite formation; increased on-treatment platelet reactivity; increased risk for adverse cardiac and cerebrovascular events"},"drugrecommendation":"No recommendation","classification":"No Recommendation","phenotypes":{"CYP2C19": "Intermediate Metabolizer"},"activityscore":{},"population":"CVI non-ACS non-PCI","comments":"For non-acute coronary syndrome (non-ACS) and non-percutaneous coronary intervention (non-PCI) cardiovascular indications. Non-ACS, non-PCI cardiovascular indications include peripheral arterial disease and stable coronary artery disease following a recent myocardial infarction outside the setting of PCI."}, 
 {"recommendationid":7715743,"lookupkey":{"CYP2C19": "Likely Poor Metabolizer"},"drugname":"clopidogrel","guidelinename":"CYP2C19 and Clopidogrel","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-clopidogrel-and-cyp2c19/","implications":{"CYP2C19": "Significantly reduced clopidogrel active metabolite formation; increased on-treatment platelet reactivity; increased risk for adverse cardiac and cerebrovascular events"},"drugrecommendation":"Avoid clopidogrel if possible. Use prasugrel or ticagrelor at standard dose if no contraindication.","classification":"Moderate","phenotypes":{"CYP2C19": "Likely Poor Metabolizer"},"activityscore":{},"population":"CVI non-ACS non-PCI","comments":"For non-acute coronary syndrome (non-ACS) and non-percutaneous coronary intervention (non-PCI) cardiovascular indications. Non-ACS, non-PCI cardiovascular indications include peripheral arterial disease and stable coronary artery disease following a recent myocardial infarction outside the setting of PCI. The strength of recommendation for \"likely\" phenotypes are the same as their respective confirmed phenotypes. \"Likely\" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding \"likely\" phenotype."}, 
 {"recommendationid":7715744,"lookupkey":{"CYP2C19": "Poor Metabolizer"},"drugname":"clopidogrel","guidelinename":"CYP2C19 and Clopidogrel","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-clopidogrel-and-cyp2c19/","implications":{"CYP2C19": "Significantly reduced clopidogrel active metabolite formation; increased on-treatment platelet reactivity; increased risk for adverse cardiac and cerebrovascular events"},"drugrecommendation":"Avoid clopidogrel if possible. Use prasugrel or ticagrelor at standard dose if no contraindication.","classification":"Moderate","phenotypes":{"CYP2C19": "Poor Metabolizer"},"activityscore":{},"population":"CVI non-ACS non-PCI","comments":"For non-acute coronary syndrome (non-ACS) and non-percutaneous coronary intervention (non-PCI) cardiovascular indications. Non-ACS, non-PCI cardiovascular indications include peripheral arterial disease and stable coronary artery disease following a recent myocardial infarction outside the setting of PCI."}, 
 {"recommendationid":7715745,"lookupkey":{"CYP2C19": "Indeterminate"},"drugname":"clopidogrel","guidelinename":"CYP2C19 and Clopidogrel","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-clopidogrel-and-cyp2c19/","implications":{"CYP2C19": "n/a"},"drugrecommendation":"No recommendation","classification":"No Recommendation","phenotypes":{"CYP2C19": "Indeterminate"},"activityscore":{},"population":"CVI non-ACS non-PCI","comments":"n/a"}, 
 {"recommendationid":7715746,"lookupkey":{"CYP2C19": "Ultrarapid Metabolizer"},"drugname":"clopidogrel","guidelinename":"CYP2C19 and Clopidogrel","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-clopidogrel-and-cyp2c19/","implications":{"CYP2C19": "Increased clopidogrel active metabolite formation; lower on-treatment platelet reactivity"},"drugrecommendation":"No recommendation","classification":"No Recommendation","phenotypes":{"CYP2C19": "Ultrarapid Metabolizer"},"activityscore":{},"population":"NVI","comments":"For neurovascular indications. Neurovascular disease includes acute ischemic stroke or transient ischemic attack, secondary prevention of stroke, or prevention of thromboembolic events following neurointerventional procedures such as carotid artery stenting and stent-assisted coiling of intracranial aneurysms."}, 
 {"recommendationid":7715747,"lookupkey":{"CYP2C19": "Rapid Metabolizer"},"drugname":"clopidogrel","guidelinename":"CYP2C19 and Clopidogrel","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-clopidogrel-and-cyp2c19/","implications":{"CYP2C19": "Normal or increased clopidogrel active metabolite formation; normal or lower on-treatment platelet reactivity"},"drugrecommendation":"No recommendation","classification":"No Recommendation","phenotypes":{"CYP2C19": "Rapid Metabolizer"},"activityscore":{},"population":"NVI","comments":"For neurovascular indications. Neurovascular disease includes acute ischemic stroke or transient ischemic attack, secondary prevention of stroke, or prevention of thromboembolic events following neurointerventional procedures such as carotid artery stenting and stent-assisted coiling of intracranial aneurysms."}, 
 {"recommendationid":7715748,"lookupkey":{"CYP2C19": "Normal Metabolizer"},"drugname":"clopidogrel","guidelinename":"CYP2C19 and Clopidogrel","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-clopidogrel-and-cyp2c19/","implications":{"CYP2C19": "Normal clopidogrel active metabolite formation; normal on-treatment platelet reactivity"},"drugrecommendation":"If considering clopidogrel, use at standard dose (75 mg/day)","classification":"Strong","phenotypes":{"CYP2C19": "Normal Metabolizer"},"activityscore":{},"population":"NVI","comments":"For neurovascular indications. Neurovascular disease includes acute ischemic stroke or transient ischemic attack, secondary prevention of stroke, or prevention of thromboembolic events following neurointerventional procedures such as carotid artery stenting and stent-assisted coiling of intracranial aneurysms."}, 
 {"recommendationid":7715749,"lookupkey":{"CYP2C19": "Likely Intermediate Metabolizer"},"drugname":"clopidogrel","guidelinename":"CYP2C19 and Clopidogrel","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-clopidogrel-and-cyp2c19/","implications":{"CYP2C19": "Reduced clopidogrel active metabolite formation; increased on-treatment platelet reactivity; increased risk for adverse cardiac and cerebrovascular events"},"drugrecommendation":"Consider an alternative P2Y12 inhibitor at standard dose if clinically indicated and no contraindication.","classification":"Moderate","phenotypes":{"CYP2C19": "Likely Intermediate Metabolizer"},"activityscore":{},"population":"NVI","comments":"For neurovascular indications. Neurovascular disease includes acute ischemic stroke or transient ischemic attack, secondary prevention of stroke, or prevention of thromboembolic events following neurointerventional procedures such as carotid artery stenting and stent-assisted coiling of intracranial aneurysms. Alternative P2Y12 inhibitors not impacted by CYP2C19 genetic variants include ticagrelor and ticlopidine. Prasugrel is contraindicated in patients with a history of stroke or TIA. Given limited outcomes data for genotype-guided anti-platelet therapy for neurovascular indications, selection of therapy should depend on individual patient treatment goals and risks for adverse events. The strength of recommendation for \"likely\" phenotypes are the same as their respective confirmed phenotypes. \"Likely\" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding \"likely\" phenotype."}, 
 {"recommendationid":7715750,"lookupkey":{"CYP2C19": "Intermediate Metabolizer"},"drugname":"clopidogrel","guidelinename":"CYP2C19 and Clopidogrel","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-clopidogrel-and-cyp2c19/","implications":{"CYP2C19": "Reduced clopidogrel active metabolite formation; increased on-treatment platelet reactivity; increased risk for adverse cardiac and cerebrovascular events"},"drugrecommendation":"Consider an alternative P2Y12 inhibitor at standard dose if clinically indicated and no contraindication.","classification":"Moderate","phenotypes":{"CYP2C19": "Intermediate Metabolizer"},"activityscore":{},"population":"NVI","comments":"For neurovascular indications. Neurovascular disease includes acute ischemic stroke or transient ischemic attack, secondary prevention of stroke, or prevention of thromboembolic events following neurointerventional procedures such as carotid artery stenting and stent-assisted coiling of intracranial aneurysms. Alternative P2Y12 inhibitors not impacted by CYP2C19 genetic variants include ticagrelor and ticlopidine. Prasugrel is contraindicated in patients with a history of stroke or TIA. Given limited outcomes data for genotype-guided anti-platelet therapy for neurovascular indications, selection of therapy should depend on individual patient treatment goals and risks for adverse events."}, 
 {"recommendationid":7715751,"lookupkey":{"CYP2C19": "Likely Poor Metabolizer"},"drugname":"clopidogrel","guidelinename":"CYP2C19 and Clopidogrel","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-clopidogrel-and-cyp2c19/","implications":{"CYP2C19": "Significantly reduced clopidogrel active metabolite formation; increased on-treatment platelet reactivity; increased risk for adverse cardiac and cerebrovascular events"},"drugrecommendation":"Avoid clopidogrel if possible. Consider an alternative P2Y12 inhibitor at standard dose if clinically indicated and no contraindication.","classification":"Moderate","phenotypes":{"CYP2C19": "Likely Poor Metabolizer"},"activityscore":{},"population":"NVI","comments":"For neurovascular indications. Neurovascular disease includes acute ischemic stroke or transient ischemic attack, secondary prevention of stroke, or prevention of thromboembolic events following neurointerventional procedures such as carotid artery stenting and stent-assisted coiling of intracranial aneurysms. Alternative P2Y12 inhibitors not impacted by CYP2C19 genetic variants include ticagrelor and ticlopidine. Prasugrel is contraindicated in patients with a history of stroke or TIA. Given limited outcomes data for genotype-guided anti-platelet therapy for neurovascular indications, selection of therapy should depend on individual patient treatment goals and risks for adverse events. The strength of recommendation for \"likely\" phenotypes are the same as their respective confirmed phenotypes. \"Likely\" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding \"likely\" phenotype."}, 
 {"recommendationid":7715752,"lookupkey":{"CYP2C19": "Poor Metabolizer"},"drugname":"clopidogrel","guidelinename":"CYP2C19 and Clopidogrel","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-clopidogrel-and-cyp2c19/","implications":{"CYP2C19": "Significantly reduced clopidogrel active metabolite formation; increased on-treatment platelet reactivity; increased risk for adverse cardiac and cerebrovascular events"},"drugrecommendation":"Avoid clopidogrel if possible. Consider an alternative P2Y12 inhibitor at standard dose if clinically indicated and no contraindication.","classification":"Moderate","phenotypes":{"CYP2C19": "Poor Metabolizer"},"activityscore":{},"population":"NVI","comments":"For neurovascular indications. Neurovascular disease includes acute ischemic stroke or transient ischemic attack, secondary prevention of stroke, or prevention of thromboembolic events following neurointerventional procedures such as carotid artery stenting and stent-assisted coiling of intracranial aneurysms. Alternative P2Y12 inhibitors not impacted by CYP2C19 genetic variants include ticagrelor and ticlopidine. Prasugrel is contraindicated in patients with a history of stroke or TIA. Given limited outcomes data for genotype-guided anti-platelet therapy for neurovascular indications, selection of therapy should depend on individual patient treatment goals and risks for adverse events."}, 
 {"recommendationid":7715753,"lookupkey":{"CYP2C19": "Indeterminate"},"drugname":"clopidogrel","guidelinename":"CYP2C19 and Clopidogrel","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-clopidogrel-and-cyp2c19/","implications":{"CYP2C19": "n/a"},"drugrecommendation":"No recommendation","classification":"No Recommendation","phenotypes":{"CYP2C19": "Indeterminate"},"activityscore":{},"population":"NVI","comments":"n/a"}, 
 {"recommendationid":7715754,"lookupkey":{"CYP2D6": "n/a"},"drugname":"codeine","guidelinename":"CYP2D6, OPRM1, COMT, and Opioids","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/","implications":{"CYP2D6": "n/a"},"drugrecommendation":"No recommendation","classification":"No Recommendation","phenotypes":{"CYP2D6": "Indeterminate"},"activityscore":{"CYP2D6": "n/a"},"population":"general","comments":"n/a"}, 
 {"recommendationid":7715755,"lookupkey":{"CYP2D6": "0.25"},"drugname":"codeine","guidelinename":"CYP2D6, OPRM1, COMT, and Opioids","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/","implications":{"CYP2D6": "Reduced morphine formation"},"drugrecommendation":"Use codeine label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider a non-tramadol opioid.","classification":"Moderate","phenotypes":{"CYP2D6": "Intermediate Metabolizer"},"activityscore":{"CYP2D6": "0.25"},"population":"general","comments":"n/a"}, 
 {"recommendationid":7715756,"lookupkey":{"CYP2D6": "0.5"},"drugname":"codeine","guidelinename":"CYP2D6, OPRM1, COMT, and Opioids","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/","implications":{"CYP2D6": "Reduced morphine formation"},"drugrecommendation":"Use codeine label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider a non-tramadol opioid.","classification":"Moderate","phenotypes":{"CYP2D6": "Intermediate Metabolizer"},"activityscore":{"CYP2D6": "0.5"},"population":"general","comments":"n/a"}, 
 {"recommendationid":7715757,"lookupkey":{"CYP2D6": "0.75"},"drugname":"codeine","guidelinename":"CYP2D6, OPRM1, COMT, and Opioids","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/","implications":{"CYP2D6": "Reduced morphine formation"},"drugrecommendation":"Use codeine label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider a non-tramadol opioid.","classification":"Moderate","phenotypes":{"CYP2D6": "Intermediate Metabolizer"},"activityscore":{"CYP2D6": "0.75"},"population":"general","comments":"n/a"}, 
 {"recommendationid":7715758,"lookupkey":{"CYP2D6": "1.0"},"drugname":"codeine","guidelinename":"CYP2D6, OPRM1, COMT, and Opioids","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/","implications":{"CYP2D6": "Reduced morphine formation"},"drugrecommendation":"Use codeine label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider a non-tramadol opioid.","classification":"Moderate","phenotypes":{"CYP2D6": "Intermediate Metabolizer"},"activityscore":{"CYP2D6": "1.0"},"population":"general","comments":"n/a"}, 
 {"recommendationid":7715759,"lookupkey":{"CYP2D6": "1.25"},"drugname":"codeine","guidelinename":"CYP2D6, OPRM1, COMT, and Opioids","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/","implications":{"CYP2D6": "Expected morphine formation"},"drugrecommendation":"Use codeine label recommended age- or weight-specific dosing.","classification":"Strong","phenotypes":{"CYP2D6": "Normal Metabolizer"},"activityscore":{"CYP2D6": "1.25"},"population":"general","comments":"n/a"}, 
 {"recommendationid":7715760,"lookupkey":{"CYP2D6": "1.5"},"drugname":"codeine","guidelinename":"CYP2D6, OPRM1, COMT, and Opioids","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/","implications":{"CYP2D6": "Expected morphine formation"},"drugrecommendation":"Use codeine label recommended age- or weight-specific dosing.","classification":"Strong","phenotypes":{"CYP2D6": "Normal Metabolizer"},"activityscore":{"CYP2D6": "1.5"},"population":"general","comments":"n/a"}, 
 {"recommendationid":7715761,"lookupkey":{"CYP2D6": "1.75"},"drugname":"codeine","guidelinename":"CYP2D6, OPRM1, COMT, and Opioids","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/","implications":{"CYP2D6": "Expected morphine formation"},"drugrecommendation":"Use codeine label recommended age- or weight-specific dosing.","classification":"Strong","phenotypes":{"CYP2D6": "Normal Metabolizer"},"activityscore":{"CYP2D6": "1.75"},"population":"general","comments":"n/a"}, 
 {"recommendationid":7715762,"lookupkey":{"CYP2D6": "2.0"},"drugname":"codeine","guidelinename":"CYP2D6, OPRM1, COMT, and Opioids","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/","implications":{"CYP2D6": "Expected morphine formation"},"drugrecommendation":"Use codeine label recommended age- or weight-specific dosing.","classification":"Strong","phenotypes":{"CYP2D6": "Normal Metabolizer"},"activityscore":{"CYP2D6": "2.0"},"population":"general","comments":"n/a"}, 
 {"recommendationid":7715763,"lookupkey":{"CYP2D6": "2.25"},"drugname":"codeine","guidelinename":"CYP2D6, OPRM1, COMT, and Opioids","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/","implications":{"CYP2D6": "Expected morphine formation"},"drugrecommendation":"Use codeine label recommended age- or weight-specific dosing.","classification":"Strong","phenotypes":{"CYP2D6": "Normal Metabolizer"},"activityscore":{"CYP2D6": "2.25"},"population":"general","comments":"n/a"}, 
 {"recommendationid":7715764,"lookupkey":{"CYP2D6": "0.0"},"drugname":"codeine","guidelinename":"CYP2D6, OPRM1, COMT, and Opioids","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/","implications":{"CYP2D6": "Greatly reduced morphine formation leading to diminished analgesia."},"drugrecommendation":"Avoid codeine use because of possibility of diminished analgesia. If opioid use is warranted, consider a non-tramadol opioid.","classification":"Strong","phenotypes":{"CYP2D6": "Poor Metabolizer"},"activityscore":{"CYP2D6": "0.0"},"population":"general","comments":"n/a"}, 
 {"recommendationid":7715765,"lookupkey":{"CYP2D6": "2.5"},"drugname":"codeine","guidelinename":"CYP2D6, OPRM1, COMT, and Opioids","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/","implications":{"CYP2D6": "Increased formation of morphine leading to higher risk of toxicity"},"drugrecommendation":"Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.","classification":"Strong","phenotypes":{"CYP2D6": "Ultrarapid Metabolizer"},"activityscore":{"CYP2D6": "2.5"},"population":"general","comments":"n/a"}, 
 {"recommendationid":7715766,"lookupkey":{"CYP2D6": "3.0"},"drugname":"codeine","guidelinename":"CYP2D6, OPRM1, COMT, and Opioids","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/","implications":{"CYP2D6": "Increased formation of morphine leading to higher risk of toxicity"},"drugrecommendation":"Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.","classification":"Strong","phenotypes":{"CYP2D6": "Ultrarapid Metabolizer"},"activityscore":{"CYP2D6": "3.0"},"population":"general","comments":"n/a"}, 
 {"recommendationid":7715767,"lookupkey":{"CYP2D6": "2.75"},"drugname":"codeine","guidelinename":"CYP2D6, OPRM1, COMT, and Opioids","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/","implications":{"CYP2D6": "Increased formation of morphine leading to higher risk of toxicity"},"drugrecommendation":"Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.","classification":"Strong","phenotypes":{"CYP2D6": "Ultrarapid Metabolizer"},"activityscore":{"CYP2D6": "2.75"},"population":"general","comments":"n/a"}, 
 {"recommendationid":7715768,"lookupkey":{"CYP2D6": "4.0"},"drugname":"codeine","guidelinename":"CYP2D6, OPRM1, COMT, and Opioids","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/","implications":{"CYP2D6": "Increased formation of morphine leading to higher risk of toxicity"},"drugrecommendation":"Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.","classification":"Strong","phenotypes":{"CYP2D6": "Ultrarapid Metabolizer"},"activityscore":{"CYP2D6": "4.0"},"population":"general","comments":"n/a"}, 
 {"recommendationid":7715769,"lookupkey":{"CYP2D6": "≥3.0"},"drugname":"codeine","guidelinename":"CYP2D6, OPRM1, COMT, and Opioids","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/","implications":{"CYP2D6": "Increased formation of morphine leading to higher risk of toxicity"},"drugrecommendation":"Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.","classification":"Strong","phenotypes":{"CYP2D6": "Ultrarapid Metabolizer"},"activityscore":{"CYP2D6": "≥3.0"},"population":"general","comments":"n/a"}, 
 {"recommendationid":7715770,"lookupkey":{"CYP2D6": "≥3.25"},"drugname":"codeine","guidelinename":"CYP2D6, OPRM1, COMT, and Opioids","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/","implications":{"CYP2D6": "Increased formation of morphine leading to higher risk of toxicity"},"drugrecommendation":"Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.","classification":"Strong","phenotypes":{"CYP2D6": "Ultrarapid Metabolizer"},"activityscore":{"CYP2D6": "≥3.25"},"population":"general","comments":"n/a"}, 
 {"recommendationid":7715771,"lookupkey":{"CYP2D6": "≥3.5"},"drugname":"codeine","guidelinename":"CYP2D6, OPRM1, COMT, and Opioids","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/","implications":{"CYP2D6": "Increased formation of morphine leading to higher risk of toxicity"},"drugrecommendation":"Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.","classification":"Strong","phenotypes":{"CYP2D6": "Ultrarapid Metabolizer"},"activityscore":{"CYP2D6": "≥3.5"},"population":"general","comments":"n/a"}, 
 {"recommendationid":7715772,"lookupkey":{"CYP2D6": "≥4.0"},"drugname":"codeine","guidelinename":"CYP2D6, OPRM1, COMT, and Opioids","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/","implications":{"CYP2D6": "Increased formation of morphine leading to higher risk of toxicity"},"drugrecommendation":"Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.","classification":"Strong","phenotypes":{"CYP2D6": "Ultrarapid Metabolizer"},"activityscore":{"CYP2D6": "≥4.0"},"population":"general","comments":"n/a"}, 
 {"recommendationid":7716089,"lookupkey":{"DPYD": "2.0"},"drugname":"fluorouracil","guidelinename":"DPYD and Fluoropyrimidines","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/","implications":{"DPYD": "Normal DPD activity and \"normal\" risk for fluoropyrimidine toxicity"},"drugrecommendation":"Based on genotype, there is no indication to change dose or therapy. Use label-recommended dosage and administration.","classification":"Strong","phenotypes":{"DPYD": "Normal Metabolizer"},"activityscore":{"DPYD": "2.0"},"population":"general","comments":"n/a"}, 
 {"recommendationid":7716090,"lookupkey":{"DPYD": "1.5"},"drugname":"fluorouracil","guidelinename":"DPYD and Fluoropyrimidines","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/","implications":{"DPYD": "Decreased DPD activity (leukocyte DPD activity at 30% to 70% that of the normal population) and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs"},"drugrecommendation":"Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available).","classification":"Moderate","phenotypes":{"DPYD": "Intermediate Metabolizer"},"activityscore":{"DPYD": "1.5"},"population":"general","comments":"Increase the dose in patients experiencing no or clinically tolerable toxicity in the first two cycles to maintain efficacy; decrease the dose in patients who do not tolerate the starting dose to minimize toxicities."}, 
 {"recommendationid":7716091,"lookupkey":{"DPYD": "1.0"},"drugname":"fluorouracil","guidelinename":"DPYD and Fluoropyrimidines","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/","implications":{"DPYD": "Decreased DPD activity (leukocyte DPD activity at 30% to 70% that of the normal population) and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs"},"drugrecommendation":"Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available). Patients with the c.2846A>T/c.2846A>T genotype may require >50% reduction in starting dose.","classification":"Strong","phenotypes":{"DPYD": "Intermediate Metabolizer"},"activityscore":{"DPYD": "1.0"},"population":"general","comments":"Increase the dose in patients experiencing no or clinically tolerable toxicity in the first two cycles to maintain efficacy; decrease the dose in patients who do not tolerate the starting dose to minimize toxicities."}, 
 {"recommendationid":7716092,"lookupkey":{"DPYD": "0.5"},"drugname":"fluorouracil","guidelinename":"DPYD and Fluoropyrimidines","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/","implications":{"DPYD": "Complete DPD deficiency and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs."},"drugrecommendation":"Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens. In the event, based on clinical advice, alternative agents are not considered a suitable therapeutic option, 5-fluorouracil should be administered at a strongly reduced dose with early therapeutic drug monitoring.","classification":"Strong","phenotypes":{"DPYD": "Poor Metabolizer"},"activityscore":{"DPYD": "0.5"},"population":"general","comments":"If available, a phenotyping test (see main text for further details) should be considered to estimate the starting dose. In absence of phenotyping data, a dose of <25% of the normal starting dose is estimated assuming additive effects of alleles on 5-FU clearance. Therapeutic drug monitoring should be done at the earliest time point possible (e.g., minimum time point in steady state) in order to immediately discontinue therapy if the drug level is too high."}, 
 {"recommendationid":7716093,"lookupkey":{"DPYD": "0.0"},"drugname":"fluorouracil","guidelinename":"DPYD and Fluoropyrimidines","guidelineurl":"https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/","implications":{"DPYD": "Complete DPD deficiency and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs."},"drugrecommendation":"Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens.","classification":"Strong","phenotypes":{"DPYD": "Poor Metabolizer"},"activityscore":{"DPYD": "0.0"},"population":"general","comments":"n/a"}, 
 {"recommendationid":7716835,"lookupkey":{"SLCO1B1": "Increased Function"},"drugname":"simvastatin","guidelinename":"SLCO1B1, ABCG2, CYP2C9, and Statins","guidelineurl":"https://cpicpgx.org/guidelines/cpic-guideline-for-statins/","implications":{"SLCO1B1": "Typical myopathy risk and statin exposure"},"drugrecommendation":"Prescribe desired starting dose and adjust doses based on disease-specific guidelines.","classification":"Strong","phenotypes":{"SLCO1B1": "Increased Function"},"activityscore":{},"population":"general","comments":"The potential for drug-drug interactions and dose limits based on renal and hepatic function and ancestry should be evaluated prior to initiating a statin."}, 
 {"recommendationid":7716836,"lookupkey":{"SLCO1B1": "Normal Function"},"drugname":"simvastatin","guidelinename":"SLCO1B1, ABCG2, CYP2C9, and Statins","guidelineurl":"https://cpicpgx.org/guidelines/cpic-guideline-for-statins/","implications":{"SLCO1B1": "Typical myopathy risk and statin exposure"},"drugrecommendation":"Prescribe desired starting dose and adjust doses based on disease-specific guidelines.","classification":"Strong","phenotypes":{"SLCO1B1": "Normal Function"},"activityscore":{},"population":"general","comments":"The potential for drug-drug interactions and dose limits based on renal and hepatic function and ancestry should be evaluated prior to initiating a statin."}, 
 {"recommendationid":7716837,"lookupkey":{"SLCO1B1": "Possible Decreased Function"},"drugname":"simvastatin","guidelinename":"SLCO1B1, ABCG2, CYP2C9, and Statins","guidelineurl":"https://cpicpgx.org/guidelines/cpic-guideline-for-statins/","implications":{"SLCO1B1": "Increased simvastatin acid exposure as compared to normal function; increased risk of myopathy"},"drugrecommendation":"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to <20mg/day.","classification":"Strong","phenotypes":{"SLCO1B1": "Possible Decreased Function"},"activityscore":{},"population":"general","comments":"The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."}, 
 {"recommendationid":7716838,"lookupkey":{"SLCO1B1": "Decreased Function"},"drugname":"simvastatin","guidelinename":"SLCO1B1, ABCG2, CYP2C9, and Statins","guidelineurl":"https://cpicpgx.org/guidelines/cpic-guideline-for-statins/","implications":{"SLCO1B1": "Increased simvastatin acid exposure as compared to normal function; increased risk of myopathy"},"drugrecommendation":"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to <20mg/day.","classification":"Strong","phenotypes":{"SLCO1B1": "Decreased Function"},"activityscore":{},"population":"general","comments":"The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."}, 
 {"recommendationid":7716839,"lookupkey":{"SLCO1B1": "Poor Function"},"drugname":"simvastatin","guidelinename":"SLCO1B1, ABCG2, CYP2C9, and Statins","guidelineurl":"https://cpicpgx.org/guidelines/cpic-guideline-for-statins/","implications":{"SLCO1B1": "Increased simvastatin acid exposure compared to normal and decreased function; highly increased myopathy risk"},"drugrecommendation":"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins).","classification":"Strong","phenotypes":{"SLCO1B1": "Poor Function"},"activityscore":{},"population":"general","comments":"The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."}, 
 {"recommendationid":7716840,"lookupkey":{"SLCO1B1": "Indeterminate"},"drugname":"simvastatin","guidelinename":"SLCO1B1, ABCG2, CYP2C9, and Statins","guidelineurl":"https://cpicpgx.org/guidelines/cpic-guideline-for-statins/","implications":{"SLCO1B1": "n/a"},"drugrecommendation":"No recommendation","classification":"No Recommendation","phenotypes":{"SLCO1B1": "Indeterminate"},"activityscore":{},"population":"general","comments":"n/a"}]